Shopping Cart
- Remove All
Your shopping cart is currently empty
BBC0403 is a selective BRD2 inhibitor that inhibits BRD2 and BRD2, suppressing NF-κB and MAPK signaling pathways. It can be used in osteoarthritis (OA) research.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $57 | In Stock | |
| 5 mg | $133 | In Stock | |
| 10 mg | $215 | In Stock | |
| 25 mg | $397 | In Stock | |
| 50 mg | $569 | In Stock | |
| 100 mg | $786 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $141 | In Stock |
| Description | BBC0403 is a selective BRD2 inhibitor that inhibits BRD2 and BRD2, suppressing NF-κB and MAPK signaling pathways. It can be used in osteoarthritis (OA) research. |
| Targets&IC50 | BRD2 (BD2):7.64 μM (Kd), BRD2 (BD1):41.37 μM (Kd) |
| In vitro | BBC0403 is a selective BRD2 inhibitor with Kd values of 7.64 μM for BRD2 (BD2) and 41.37 μM for BRD2 (BD1).BBC0403 significantly inhibited the expression of catabolic factors, the production of prostaglandin E2 (PGE2) and the degradation of the extracellular matrix (ECM) after treatment with BBC0403 at 5 μM, 10 μM, and 20 μM for 12 h. BBC0403 inhibits catabolic factor expression, prostaglandin E2 (PGE2) production, and the degradation of ECM. and extracellular matrix (ECM) degradation. By blocking the NF-κB and MAPK signaling pathways, BBC0403 helps to alleviate the development of osteoarthritis (OA). [1] |
| In vivo | Weekly intra-articular injection of 5-10 μg/kg of BBC0403 for 6 weeks effectively prevented the degradation of osteoarthritic cartilage in a mouse model. [1] |
| Synonyms | BBC 0403 |
| Molecular Weight | 382.41 |
| Formula | C21H22N2O5 |
| Cas No. | 2644662-83-7 |
| Smiles | O=C1N=C(NC=2C=C(OC)C=C(OC)C12)C=3C=C(C(OC4COC4)=C(C3)C)C |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (52.3 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.23 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.